Highlights of weekly biotech stock moves

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) rose $0.67 to $15.93 on Friday after EMA's CHMP issued a positive opinion for an MAA for Rienso ferumoxytol submitted by partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to treat iron deficiency anemia in chronic kidney disease patients. The stock was up $0.28 last week.

Halozyme Therapeutics Inc. (NASDAQ:HALO) fell $2.72 (24%) to $8.56 on Monday after FDA said it needs additional information before completing its review of HyQvia for primary immunodeficiency disorder. According to Halozyme and partner Baxter International Inc. (NYSE:BAX), FDA requested more data - either from clinical or preclinical studies - on the long-term use of HyQvia, but did not issue a complete response letter. HyQvia is a subcutaneous formulation of IV Gammagard, an IgG antibodies plasma-based therapy, and rHuPH20, a recombinant human PH20 hyaluronidase enzyme...